Catalyst Pharmaceuticals, Inc. CPRX

Name: CPRX Crucible Score
Creator: Kaladin Capital Intelligence

HealthcareBiotechnologyNASDAQ📅 Scored March 16, 2026

Price at analysis: $24.06

Crucible Score

73.8

B+

Quality × Value Composite

KQI — Quality

69.0

Fundamental Quality Index

KVI — Value

79.6

B+

Valuation Attractiveness Index

Crucible Verdict — CPRX

Catalyst Pharmaceuticals, Inc. (CPRX) shows solid financial quality at 88 but suffers from poor diversification at just 27, reflecting its narrow focus on rare disease treatments. The stock trades at a significant 48% discount to fair value despite an impressive 83% earnings beat rate. CPRX's concentrated business model creates both opportunity and risk as it depends heavily on limited therapeutic areas.

— Kal, Kaladin Capital Intelligence

◆ KQI Quality Dimensions

Financial Quality

88.0

Growth Profile

66.4

Moat Durability

64.8

Management Effectiveness

70.8

Diversification & Resilience

26.8

Market Position

62.0

Weakest dimension: Diversification & Resilience (26.8)

◆ KVI Value Dimensions

DCF Margin of Safety

81.8

FCF Yield & Cash Returns

67.7

Relative Valuation

85.6

Growth-Adjusted Value

85.4

Historical Valuation

75.6

Macro Context

91.1

◆ DCF Valuation Scenarios

Bear Case

$22.48

Base Case

$35.72

Bull Case

$52.89

Price at Analysis

$24.06

Scenario	Fair Value	Rev CAGR (5yr)	Terminal Margin	WACC
🔴 Bear	$22.48	8.0%	38.0%	9.3%
🟢 Base	$35.72	12.0%	43.0%	8.7%
🟢 Bull	$52.89	16.0%	47.0%	8.1%

Key Assumptions: CPRX has demonstrated exceptional revenue growth (~33% CAGR over 5 years) driven by Inbrija and XYWAV/XYREM franchise expansion, with operating margins stabilizing in the 40-48% range. Base case assumes growth moderates to 12% as the product portfolio matures but maintains strong margins given minimal capex needs. Bear case reflects potential generic competition or pricing pressure compressing margins to 38%, while bull case assumes successful pipeline additions sustaining 16% growth with margin expansion to 47%.

◆ Financial Snapshot

Profitability

Gross Margin85.2%

Operating Margin43.8%

Net Margin36.4%

ROIC20.3%

ROE5.5%

Balance Sheet

Balance SheetCR: 6.08

Cash ConversionFCF/EPS: 0.98x

Capital IntensityCapex/Rev: 0.0%

Altman Z-Score13.99 (Safe)

Piotroski F-Score5/9 (Mixed)

Growth

Revenue CAGR43.0% CAGR

Earnings CAGR52.6% CAGR

Growth ConsistencyCV: 2.42

Segment Breadth1/2 growing (50%)

Quarterly TrendRev↘+8%, Margin↘, WC↓, Exp↓

Earnings CredibilityConsistent Beater

◆ Revenue Breakdown — FY2025

By Segment

Product Revenue Net100.0%

License And Other Revenue0.0%

By Geography

Non-US100.0%

Total Revenue

$2.3M

Fiscal Year 2025

◆ Analyst Consensus & Leadership

Analyst Price Targets

Avg Target (Last Quarter)$0.00

Analysts Covering (Quarter)0

Avg Target (Last Year)$33.00

Analysts (Year)1

Leadership & Governance

CEO Ownership10.4%

Compensation89% performance-based

Insider ActivitySelling

Capital AllocationROIC 20.3% vs WACC 8.4%

Earnings Beat Rate83% (17/22)

◆ Company Profile

Catalyst Pharmaceuticals, Inc. , a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States.

CEO

Richard John Daly

Employees

181

Headquarters

Coral Gables, FL, US

IPO Date

November 8, 2006

Exchange

NASDAQ

Website

catalystpharma.com

◆ Related Companies in Our Universe

Other Healthcare companies scored by the Crucible:

ADBE81.8A-NICE80.7A-DECK79.9A-INTU79.9A-EXEL78.3A-MTCH78.2A-TTD78.0B+

Methodology All Scores Crucible Briefs Performance @KaladinCI

Analysis conducted March 16, 2026 based on most recent SEC filings. Updated quarterly, after new SEC filings.

Point-in-time fundamental analysis. Not investment advice. Scores reflect company quality and valuation at time of analysis and may not reflect current market conditions.